| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_332b293f8a27d8dfcc89af550267b295 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2006-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3160feba5039551d9078cc8cbc881e94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59ec4bfbbd09bfa3c3085d973be17b46 |
| publicationDate |
2008-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20080100806-A |
| titleOfInvention |
Use of anti-BCD40 antibody |
| abstract |
The present invention provides a method of treating an inflammatory disease or autoimmune disease associated with CD40-expressing cells in a human patient, wherein the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V / F or F / F). Also provided are methods for inhibiting antibody production by B cells in human patients who are heterozygous or homozygous (genotype V / F or F / F) to FcγRIIIa-158F. The method comprises administering to a human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying human patients who have an inflammatory disease or autoimmune disease treatable with an anti-CD40 antibody, who are unresponsive or resistant to the treatment of Rituxima®, and an inflammatory or autoimmune disease And methods and kits for selecting therapeutic antibody therapies for human patients who are unresponsive or resistant to the treatment of Rituximab (Rituxan®). The methods of the invention find use in the treatment of cancer and precancerous conditions associated with CD40-expressing cells. This method is particularly advantageous for cancer and precancerous conditions associated with cells expressing both CD40 and CD20, which can lead to inflammatory or autoimmune diseases that are unresponsive or resistant to other tumor therapeutic therapies such as anti-CD20 antibody therapy. This is because the patient can be treated. |
| priorityDate |
2005-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |